5/26/2010 | CVHYPF | Adolor files $100 million shelf covering preferreds, debt and stock
|
11/6/2006 | BT | Adolor cut to sector perform by RBC
|
11/6/2006 | BT | Merrill puts Adolor at buy
|
11/1/2006 | BT | Adolor at buy by Merrill
|
10/31/2006 | BT | Adolor reports Q3 loss of $18.2 million, able to fund operations into 2008
|
10/31/2006 | BT | Adolor rated outperform by RBC
|
9/20/2006 | BT | Market Commentary: Incyte pitches deeply discounted drive-by convertible; Genta down 32% on PIPE; Adolor rises
|
9/20/2006 | BT | Merrill ups Adolor to buy
|
9/12/2006 | BT | Market Commentary: Oscient may bounce on expected FDA rejection; New River rises 6%; Adolor flat, Progenics lower
|
9/5/2006 | BT | GlaxoSmithKline, Adolor report mixed results from phase 3 alvimopan studies
|
9/5/2006 | BT | Merrill rates Adolor at neutral
|
9/5/2006 | BT | Adolor at outperform
|
8/30/2006 | BT | Adolor starts phase 1 study of novel Delta opioid agonist for pain management
|
8/11/2006 | BT | RBC picks Gilead, Adolor as biotech underperforms for 2006 to date
|
8/4/2006 | BT | Market Commentary: Invitrogen, CV Therapeutics plunge; Osiris debuts higher, ends steady; Adolor gets eyed
|
8/2/2006 | BT | Merrill keeps Adolor at neutral
|
8/1/2006 | BT | RBC reiterates Adolor at outperform
|
7/27/2006 | BT | Adolor reiterated at outperform by RBC
|
5/31/2006 | BT | Adolor: FDA accepts response to Entereg NDA letter
|
5/18/2006 | BT | RBC quarterly biotechnology update
|
5/4/2006 | BT | GlaxoSmithKline, Adolor alvimopan study shows improvement in opioid use-related GI symptoms
|
4/13/2006 | BT | GlaxoSmithKline, Adolor fill trial studying Entereg for gastrointestinal pain of opioids ahead of target
|
4/13/2006 | BT | Market Commentary: Adolor ends better but off highs; ArQule off amid internal changes; Hemispherx spikes 7% on PIPE
|
3/10/2006 | BT | Adolor to start phase 2 study of co-administering Hydrocodone/APAP and alvimopan
|
2/22/2006 | BT | Adolor greenshoe partially exercised, raising follow on sale to $143.75 million
|
2/16/2006 | BT | New Issue: Adolor raises $125 million in follow-on at $25, discounted from $25.19 close
|
2/16/2006 | BT | Market Commentary: Adolor up on heavy volume after deal; Avigen sinks; Biogen, Elan react to Tysabri news; Onyx slips
|
2/15/2006 | BT | Market Commentary: Pfizer peddling ¥50 billion bonds; Amgen up out of chute; Adolor at bat; Ranbaxy taps convertibles market
|
2/14/2006 | BT | Market Commentary: Amgen rejigs deal, still a magnet to convertibles, stock players; Chelsea, YM taps PIPEs; Nektar breaks out
|
2/13/2006 | BT | Adolor launches follow-on sale of 5 million shares via Lehman; to price Wednesday
|
2/13/2006 | BT | Market Commentary: Amgen up after-hours as $4 billion convert emerges; Genentech off; Adolor down on deal; Alnylam up
|
2/8/2006 | BT | Adolor kept at neutral by Merrill
|
9/28/2005 | BT | Adolor maintained by Merrill at neutral
|
8/2/2005 | BT | Adolor maintained by Merrill at neutral
|